Chronic News and Research

RSS

Discovery of a key protein’s role in cell clearance could impact future treatments of autoimmune diseases, obesity and atherosclerosis

The healthy human body is extremely efficient at cleaning house. Every day, we purge 100 to 200 billion dead or dying cells – a process called cell clearance, which is fundamental in our ability to maintain a healthy physiological balance and prevent a number of chronic diseases. Professional cleaning cells, called phagocytes, are responsible for ridding the body of dead, or ‘apoptotic,’ cells.

6 Sep 2011

Robert Gordon University scientists to develop new treatment for cystinosis

A team of researchers at Robert Gordon University has secured a six figure sum from Sparks, a leading children’s medical research charity, to develop a revolutionary treatment for a rare genetic disorder.

6 Sep 2011

Mental health problems ail nearly half of all Americans: Report

According to a new government report about half of Americans will experience some form of mental health problem at some point in their life. The report stresses that more must be done to help the population with mental health problems.

6 Sep 2011

Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced it has amended its agreement with Shiva Biomedical, LLC.

6 Sep 2011

ERS urges EU to take action on chronic respiratory diseases

Respiratory diseases are one of the leading causes of death and suffering in the EU. The challenge Europe is facing in this field goes far beyond public health: lung diseases currently cause an annual cost of €100 billion and threaten the Europe 2020 strategy and the goal to have 75% of the working population employed and productive.

6 Sep 2011

Bariatric surgery is cost-effective but has long-term complications

The majority of people who undergo bariatric weight-loss surgery benefit from the procedure, but long-term complications and further surgery are not uncommon, according to a UK paper on late postoperative complications in the October issue of BJS, the British Journal of Surgery.

6 Sep 2011

Amakem receives €18m in Series A round of funding

Amakem NV today announced it has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.

6 Sep 2011

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.

6 Sep 2011

Biologists identify mechanism of H. pylori that damages DNA of gastric mucosal cells

The stomach bacterium Helicobacter pylori is one of the biggest risk factors for the development of gastric cancer, the third most common cause of cancer-related deaths in the world.

6 Sep 2011

DaVita completes acquisition of DSI

DaVita Inc., a leading provider of kidney care services committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), announced today that it has closed its acquisition of DSI Renal, Inc.

6 Sep 2011

Moderate to severe cognitive impairment has impact on life expectancy

Cognitive impairment, even when detected at an early, mild stage, is a significant predictor of decreased life expectancy.

6 Sep 2011

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.

5 Sep 2011

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Gilead Sciences, Inc. today announced that, in consultation with the U.S. Food and Drug Administration (FDA), the company will amend the design of ongoing clinical trials to discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.

5 Sep 2011

Teenagers use medicines frequently without receiving targeted information about risks and benefits

A large proportion of teenagers regularly and frequently take some form of medication without receiving targeted information about the risks and benefits, according to a review of current research, to be presented at the annual congress of the International Pharmaceutical Federation.

5 Sep 2011

Researchers discover new genetic defect that predisposes people to leukemia, myelodysplasia

A new genetic defect that predisposes people to acute myeloid leukemia and myelodysplasia has been discovered. The mutations were found in the GATA2 gene. Among its several regulatory roles, the gene acts as a master control during the transition of primitive blood-forming cells into white blood cells.

5 Sep 2011

Inhibiting the ability of immune cells to use fatty acids slows MS progression

In a paper published today in the journal Scientific Reports, a pair of researchers at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences report that inhibiting the ability of immune cells to use fatty acids as fuel measurably slows disease progression in a mouse model of multiple sclerosis.

3 Sep 2011

ATS issues guidelines on use of FENO in different clinical settings

The American Thoracic Society has issued the first-ever guidelines on the use of fractional exhaled nitric oxide (FENO) that address when to use FENO and how to interpret FENO levels in different clinical settings.

3 Sep 2011

State roundup: Texas disability fight; rights of fetus asserted in Neb.

For Milla Powell, a 12-year-old from Austin with cerebral palsy, the little things make all the difference. Massage therapy to ease her tightened muscles. Recreational programs, in which therapists take her into the community to help her build her social skills. Music therapy to help Milla, who cannot speak, connect without words. But services like these are on the chopping block for thousands of Texans with disabilities - another casualty of the significant budget cuts that state lawmakers passed in May.

3 Sep 2011

Early treatment of chronic hip pain in young athletes may have long term impact on health

Treating young athletes with chronic hip pain may be the key to slowing or halting the progression of degenerative hip disease.

3 Sep 2011

Chronic News and Research

Discovery of a key protein’s role in cell clearance could impact future treatments of autoimmune diseases, obesity and atherosclerosis

Robert Gordon University scientists to develop new treatment for cystinosis

Mental health problems ail nearly half of all Americans: Report

Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease

ERS urges EU to take action on chronic respiratory diseases

Bariatric surgery is cost-effective but has long-term complications

Amakem receives €18m in Series A round of funding

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

Biologists identify mechanism of H. pylori that damages DNA of gastric mucosal cells

DaVita completes acquisition of DSI

Moderate to severe cognitive impairment has impact on life expectancy

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Teenagers use medicines frequently without receiving targeted information about risks and benefits

Researchers discover new genetic defect that predisposes people to leukemia, myelodysplasia

Inhibiting the ability of immune cells to use fatty acids slows MS progression

ATS issues guidelines on use of FENO in different clinical settings

State roundup: Texas disability fight; rights of fetus asserted in Neb.

Early treatment of chronic hip pain in young athletes may have long term impact on health

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News